AI Article Synopsis

  • Skin and soft tissue infections (SSTI) caused by PVL-producing Staphylococcus aureus are common and often lead to recurrent abscesses, necessitating outpatient decolonization as a recommended treatment.
  • Despite the importance of topical decolonization in managing these infections, health insurance providers frequently do not fully cover the associated costs, which can pose challenges for patients seeking effective treatment.
  • A study conducted at a German university hospital examined the costs of outpatient versus inpatient treatment for recurring PVL-SA infections, revealing that most affected patients were treated as outpatients, emphasizing the need for better insurance reimbursement policies to support effective care.

Article Abstract

Introduction: Skin and soft tissue infections (SSTI) caused by Panton-Valentine leukocidin (PVL)-producing strains of Staphylococcus aureus (PVL-SA) are associated with recurrent skin abscesses. Secondary prevention, in conjunction with primary treatment of the infection, focuses on topical decolonization. Topical decolonization is a standard procedure in cases of recurrent PVL-SA skin infections and is recommended in international guidelines. However, this outpatient treatment is often not fully reimbursed by health insurance providers, which may interfere with successful PVL-SA decolonization.

Aim: Our goal was to estimate the cost effectiveness of outpatient decolonization of patients with recurrent PVL-SA skin infections. We calculated the average cost of treatment for PVL-SA per outpatient decolonization procedure as well as per in-hospital stay.

Methods: The study was conducted between 2014 and 2018 at a German tertiary care university hospital. The cohort analyzed was obtained from the hospital's microbiology laboratory database. Data on medical costs, DRG-based diagnoses, and ICD-10 patient data was obtained from the hospital's financial controlling department. We calculated the average cost of treatment for patients admitted for treatment of PVL-SA induced skin infections. The cost of outpatient treatment is based on the German regulations of drug prices for prescription drugs.

Results: We analyzed a total of n = 466 swabs from n = 411 patients with recurrent skin infections suspected of carrying PVL-SA. PVL-SA was detected in 61.3% of all patients included in the study. Of those isolates, 80.6% were methicillin-susceptible, 19.4% methicillin-resistant. 89.8% of all patients were treated as outpatients. In 73.0% of inpatients colonized with PVL-SA the main diagnosis was SSTI. The median length of stay was 5.5 days for inpatients colonized with PVL-SA whose main diagnosis SSTI; the average cost was €2,283. The estimated costs per decolonization procedure in outpatients ranged from €50-€110, depending on the products used.

Conclusion: Our data shows that outpatient decolonization offers a highly cost-effective secondary prevention strategy, which may prevent costly inpatient treatments. Therefore, health insurance companies should consider providing coverage of outpatient treatment of recurrent PVL-SA skin and soft tissue infections.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232536PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0253633PLOS

Publication Analysis

Top Keywords

skin infections
20
outpatient treatment
16
recurrent pvl-sa
12
pvl-sa skin
12
outpatient decolonization
12
average cost
12
pvl-sa
11
skin
8
panton-valentine leukocidin
8
leukocidin pvl-producing
8

Similar Publications

Burn care and treatment differ markedly from other types of wounds, as they are significantly more prone to infections and struggle to maintain fluid balance post-burn. Moreover, the limited self-healing abilities exacerbate the likelihood of scar formation, further complicating the recovery process. To tackle these issues, an asymmetric wound dressing comprising a quercetin-loaded poly(3-hydroxybutyrate-co-4-hydroxybutyrate) (P34HB@Qu) hydrophilic layer and a zinc oxide nanoparticle-loaded, thermally treated polyvinylidene fluoride (HPVDF@ZnO) hydrophobic layer is designed.

View Article and Find Full Text PDF

Challenges and considerations in liposomal hydrogels for the treatment of infection.

Expert Opin Drug Deliv

January 2025

Drug Transport and Delivery Research Group, Department of Pharmacy, Faculty of Health Sciences, University of Tromsø The Arctic University of Norway, Tromsø, Norway.

Introduction: Liposomal hydrogels are novel drug delivery systems that comprise preformed liposomes incorporated in hydrogels destined for mostly localized drug therapy, herewith antimicrobial therapy. The formulation benefits from versatility of liposomes as lipid-based nanocarriers that enable delivery of various antimicrobials of different lipophilicities, and secondary vehicle, hydrogel, that assures better retention time of formulation at the infection site. Especially in an era of alarming antimicrobial resistance, efficient localized antimicrobial therapy that avoids systemic exposure of antimicrobial and related side effects is crucial.

View Article and Find Full Text PDF

The autoimmune/inflammatory syndrome induced by adjuvants (ASIA) is a rare condition caused by an immune response associated with over-reactivity of the immune system, triggered by adjuvants. The most common adjuvants are aluminium salts but can also be bioimplants or infectious agents. It may lead to the development of various autoimmunologic diseases.

View Article and Find Full Text PDF

Cow's milk allergy (CMA) is the most common food allergy among children. An oral food challenge (OFC) remains a mainstay of the diagnosis of CMA, especially for the non-IgE-mediated type; however, this test can be risky and time-consuming. Hence, there is a need to identify biomarkers.

View Article and Find Full Text PDF

Eumycetoma, a chronic fungal infection caused by , is a neglected tropical disease characterized by tumor-like growths that can lead to permanent disability and deformities if untreated. Predominantly affecting regions in Africa, South America, and Asia, it imposes significant physical, social, and economic burdens. Current treatments, including antifungal drugs like itraconazole, often show variable efficacy, with severe cases necessitating surgical intervention or amputation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!